TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00354744

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: Age based dosage: ≥ 3 years 1200 mg/m2, \<3 years 40 mg/kg.~Day 1 of weeks 7, 11, 15, 28, 32, 35, 38, 41 and 44.~Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: doxorubicin hydrochloride
Description: Age based dosage: ≥ 1 year: 37.5mg/m²/day, \< 1 year: treat with 50% doses calculated on a m2 basis. Total dose 75 mg/m².~Days 1 and 2 of weeks 7, 11, 15, 28 and 32.~Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etoposide
Description: Age based dosage: ≥ 1 year: 100 mg/m²/day, \< 1 year: treat with 50% doses calculated on a m2 basis.~Days 1-5 of weeks 9, 13, 17, 26 and 30.~Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ifosfamide
Description: Age based dosage: ≥ 1 year: 1800 mg/m²/day, \< 1 year: treat with 50% doses calculated on a m2 basis.~Days 1-5 of weeks 9, 13, 17, 26 and 30.~Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: irinotecan hydrochloride
Description: Dosage 50 mg/m2-max dose 100 mg/day.~Days 1-5 of weeks 1, 4, 20, 23, 47 and 50.~Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vincristine sulfate
Description: Age based dosage: ≥ 3 years 1.5 mg/m2 (max dose 2 mg), ≥ 1 year and \< 3 years 0.05 mg/kg (max dose 2 mg), \< 1 year 0.025 mg/kg.~Days 1-5 of weeks 1, 2, 3, 4, 5, 7, 8, 11, 12, 15, 16, 20, 21, 22, 23, 24, 28, 29, 32, 33, 35, 38, 41, 42, 43, 44, 47, 48, 50, and 51.~Given IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: conventional surgery
Description: Resection of the primary tumor with a surrounding envelope of normal tissue

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Description: Radiotherapy beginning at Week 20 to the primary tumor and to the metastatic sites excepting those with parameningeal tumors with intracranial extension (direct extension into the brain) and those requiring emergency radiotherapy

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: filgrastim
Description: 5 micrograms/kg/day (max 300 micrograms) beginning 24-36 hours after the last dose of chemotherapy. Continue at least 7 days, or until the ANC ≥750/μL whichever comes last.~Given subcutaneously.
Study: NCT03539328

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Humanized antibody used in cancer immunotherapy.
Study: NCT02176395

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Standard medical care
Description: Standard medical care is in accordance with China Guideline for the diagnosis and treatment of acute ischemic stroke (2010), including medical care for vital signs, control of temperature, blood pressure and glucose, improving cerebral blood circulation, antiplatelet treatment and nutritional supportive care.

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Standard medical care
Description: Standard medical care is in accordance with China Guideline for the diagnosis and treatment of acute ischemic stroke (2010), including medical care for vital signs, control of temperature, blood pressure and glucose, improving cerebral blood circulation, antiplatelet treatment and nutritional supportive care.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: 0.9% saline added into 250ml 0.9% saline by an independent research nurse, sealed with brown bag in order to make the investigators and patients blinded, using brown infusion tube for infusion
Study: NCT03539328

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Chemotherapy medication

Intervention type: DRUG
Group type: OTHER
Intervention: Gemcitabine
Description: Chemotherapy medication

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Chemotherapy medication

Intervention type: DRUG
Group type: OTHER
Intervention: Paclitaxel
Description: Chemotherapy medication

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liposomal Doxorubicin
Description: Chemotherapy medication

Intervention type: DRUG
Group type: OTHER
Intervention: Liposomal Doxorubicin
Description: Chemotherapy medication
Study: NCT04479930

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pulmonary Care Web-Based App (HappyAir App)
Description: The HappyAir app reminded the HappyAir group daily to use the app, indicating that they record medication intake, daily exercise time (minutes), level of tiredness after the exercises (good, little tired, very tired, or exhausted), and daily mood (happy, little sad, sad, or very sad). The HappyAir integrated plan was designed as a model of a therapeutic program based on communication that introduced the figure of the therapeutic educator (physiotherapist or respiratory coach) in order to design interventions focused on the patients and their needs, with minimal intervention and presence, making the patients responsible for their self-care and management of their illness. Patient and educator shared responsibility.
Study: NCT01890473

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abatacept

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abatacept
Study: NCT00983437

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Armodafinil
Study: NCT00936156

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemotherapy (carboplatin, etoposide, thiotepa)
Description: Conventional chemotherapy: carboplatin injection (160 mg/m²/day by infusion over one hour in 5 % glucose saline) administered from D1 to D5 and from D22 to D26. Etoposide injection (100 mg/m²/day by infusion over one hour in 5 % glucose saline) administered from D1 to D5 and from D22 to D26. Double intensification by high-dose chemotherapy followed by autologous PBSC rescue: thiotepa injection (200 mg/m²/day as an infusion over one hour in 200 ml/m² of 5 % GS) administered from D42 to D44 and from D63 to D65. Autologous PBSC rescue on D47 and D68. Surgical resection of any tumor residue. Irradiation of the primary tumor site and cerebrospinal axis: 54 Gy to primary tumor, 36 Gy to cerebrospinal axis. Maintenance treatment: Temozolomide 150 mg/m²/day orally for 5 days every 28 days, from 1 month after the end of irradiation. 6 cycles planned. Duration of treatment: 13 months
Study: NCT01945281

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Caspofungin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amphotericin B Deoxycholate
Study: NCT03196726

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief Cognitive Behavioral Therapy
Description: Week 1: Understanding postnatal depression Week 2: Relaxation techniques and tips to reduce stress Week 3: Positive thinking style and Self-Esteem Week 4: Relationship with partner Week 5: Relationship with infant Week 6: Relapse prevention
Study: NCT03379012

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Testosterone undecanoate and sunitinib or pazopanib
Description: Testosterone undecanoate (Nebido®) 1,000 mg (4 ml) intramuscular deeply, once before targeted therapy (sunitinib 50 mg 4/2 or pazopanib 800 mg daily)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Testosterone undecanoate and sunitinib or pazopanib
Description: Testosterone undecanoate (Nebido®) 1,000 mg (4 ml) intramuscular deeply, once before targeted therapy (sunitinib 50 mg 4/2 or pazopanib 800 mg daily)
Study: NCT02225444

Intervention type: OTHER
Intervention: OsteoAMP
Description: OsteoAMP in posterolateral fusion procedure of the lumbosacral spine
Study: NCT00264849

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omalizumab
Description: Omalizumab administered by subcutaneous injection. The dosage received was individualized based on body weight and serum IgE level.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Optimized asthma therapy
Description: Optimized asthma therapy (OAT) according to Global Initiative for Asthma (GINA) 2004 guidelines during the first 4 weeks of the run-in period of the study.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Optimized asthma therapy
Description: Optimized asthma therapy (OAT) according to Global Initiative for Asthma (GINA) 2004 guidelines during the first 4 weeks of the run-in period of the study.
Study: NCT04253041

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Effects of Instagram Exposure on Lifestyle Satisfaction
Description: Participants will complete initial measures of sociodemographic information, the Sociocultural Attitudes Towards Appearance Scale, The Physical Appearance Comparison Scale-Revised, and baseline measures of body appreciation, body satisfaction, and mood using online Visual Analogue Scales via Qualtrics. Female undergraduate students will be randomly assigned to one of three groups. The Fitspiration and Body Positive groups will view a series of 15 Fitspiration or Body Positive images sourced from Instagram while the control group will view 15 interior design images sourced from Instagram. After viewing images, participants will complete posttest measures of body satisfaction, body appreciation, and mood using Visual Analogue scales. Thereafter, participants will be provided with four, brief short answer questions regarding their perspective on the images observed.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Effects of Instagram Exposure on Lifestyle Satisfaction
Description: Participants will complete initial measures of sociodemographic information, the Sociocultural Attitudes Towards Appearance Scale, The Physical Appearance Comparison Scale-Revised, and baseline measures of body appreciation, body satisfaction, and mood using online Visual Analogue Scales via Qualtrics. Female undergraduate students will be randomly assigned to one of three groups. The Fitspiration and Body Positive groups will view a series of 15 Fitspiration or Body Positive images sourced from Instagram while the control group will view 15 interior design images sourced from Instagram. After viewing images, participants will complete posttest measures of body satisfaction, body appreciation, and mood using Visual Analogue scales. Thereafter, participants will be provided with four, brief short answer questions regarding their perspective on the images observed.
Study: NCT03196726

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: standard management based on Clinical Practice Guideline
Description: Mild depression: behavioral therapy; moderate depression: behavioral therapy and consider anti-depressant if required

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: standard management based on Clinical Practice Guideline
Description: Mild depression: behavioral therapy; moderate depression: behavioral therapy and consider anti-depressant if required
Study: NCT00691314

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Stent implantation (Wingspan, Coroflex, and TiTAN2)
Description: Stent Implantation:~Wingspan intracranial stent with Gateway PTA balloon Catheter; Coroflex\&reg - balloon expandable stent system and Coroflex Blue - Coronary Stent System; TiTAN2 Bio-active coating stent~Standard Medical Management:including antiplatelet agents(Aspirin 75\~150mg/day or Clopidogrel 75mg/day),statins(Atorvastatin 20mg/day or Simvastatin 20mg/day),risk factor lowering agents (antihypertension agents:Amlodipine 5mg/day or Benazepril 10mg/day or Valsartan 80mg/day or Nifedipine 30mg/day or Indapamide 2.5mg/day,antidiabetic agents: Metformin 0.5 tid or Glipizide 5mg tid or Acarbose 50mg tid )if necessary,interactive education program (Online medical education program, health behavior guide) .~Arms: 1

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard medical treatment
Description: Standard Medical Management:including antiplatelet agents(Aspirin 75\~150mg/day or Clopidogrel 75mg/day),statins(Atorvastatin 20mg/day or Simvastatin 20mg/day),risk factor lowering agents (antihypertension agents:Amlodipine 5mg/day or Benazepril 10mg/day or Valsartan 80mg/day or Nifedipine 30mg/day or Indapamide 2.5mg/day,antidiabetic agents: Metformin 0.5 tid or Glipizide 5mg tid or Acarbose 50mg tid )if necessary,interactive education program (Online medical education program, health behavior guide)
Study: NCT04253041

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Effects of Instagram Exposure on Lifestyle Satisfaction
Description: Participants will complete initial measures of sociodemographic information, the Sociocultural Attitudes Towards Appearance Scale, The Physical Appearance Comparison Scale-Revised, and baseline measures of body appreciation, body satisfaction, and mood using online Visual Analogue Scales via Qualtrics. Female undergraduate students will be randomly assigned to one of three groups. The Fitspiration and Body Positive groups will view a series of 15 Fitspiration or Body Positive images sourced from Instagram while the control group will view 15 interior design images sourced from Instagram. After viewing images, participants will complete posttest measures of body satisfaction, body appreciation, and mood using Visual Analogue scales. Thereafter, participants will be provided with four, brief short answer questions regarding their perspective on the images observed.
Study: NCT02949206

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participants will randomly receive matching placebo in all 3 Parts on day 1 administered via IV Route (for Part 1 and 2) and SC route (for Part 3).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participants will randomly receive matching placebo in all 3 Parts on day 1 administered via IV Route (for Part 1 and 2) and SC route (for Part 3).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participants will randomly receive matching placebo in all 3 Parts on day 1 administered via IV Route (for Part 1 and 2) and SC route (for Part 3).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participants will randomly receive matching placebo in all 3 Parts on day 1 administered via IV Route (for Part 1 and 2) and SC route (for Part 3).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participants will randomly receive matching placebo in all 3 Parts on day 1 administered via IV Route (for Part 1 and 2) and SC route (for Part 3).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participants will randomly receive matching placebo in all 3 Parts on day 1 administered via IV Route (for Part 1 and 2) and SC route (for Part 3).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participants will randomly receive matching placebo in all 3 Parts on day 1 administered via IV Route (for Part 1 and 2) and SC route (for Part 3).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participants will randomly receive matching placebo in all 3 Parts on day 1 administered via IV Route (for Part 1 and 2) and SC route (for Part 3).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participants will randomly receive matching placebo in all 3 Parts on day 1 administered via IV Route (for Part 1 and 2) and SC route (for Part 3).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 4 Factor Prothrombin Complex Concentrate (PCC)
Description: Following a single dose of JNJ-64179375, participants will receive a single IV dose of 4 factor-PCC.
Study: NCT03270150

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BTL-899
Description: BTL-899
Study: NCT02765178

Intervention type: OTHER
Intervention: Children's Motivation Scale
Description: A 16-item questionnaire to evaluate level of motivation in children and adolescents completed by the primary caregiver.

Intervention type: OTHER
Intervention: Children's Motivation Scale
Description: A 16-item questionnaire to evaluate level of motivation in children and adolescents completed by the primary caregiver.

Intervention type: OTHER
Intervention: Yale Global Tic Severity Scale (YGTSS)
Description: Clinician administered questionnaire given to Tourette patients. Part 1 asks about 10 types of motor tics, 12 types of vocal tics (current, ever, age of onset, description). Part 2 is a severity rating that scores both motor and vocal tics on a 0-5 scale for each severity item: number of tics, intensity, frequency, complexity, interference, impairment. Totals are summed for all items.

Intervention type: OTHER
Intervention: Studies Depression Scale for Children (CES-DC)
Description: Clinician administered questionnaire given to Tourette patients. Consisting of 20 items, respondents are asked to indicate how strongly they have felt a certain way during the past week using a Likert-type scale that ranges from not at all to a lot. Only two items on the questionnaire relate specifically to sleep or fatigue. CES-DC is a validated score for assessing depression in children and adolescents

Intervention type: OTHER
Intervention: Gilles de la Tourette Syndrome Quality Of Life scale
Description: Clinician administered questionnaire given to Tourette patients. Gilles de la Tourette Syndrome Quality Of Life scale (GTS-QOL) is a recently validated score for the assessment of quality of life in patients with Tourette syndrome. Consisting of a 27-item GTS-specific HR-QOL scale (GTS-QOL) with four subscales (psychological, physical, obsessional, and cognitive).

Intervention type: OTHER
Intervention: Demographic Data
Description: Data will be collected including: age, age at disease onset, gender, current medication regimen and presence of co-morbidities (like a diagnosis of ADHD, OCD, depression or insomnia).
Study: NCT04338516

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ossix™ Bone
Description: a resorbable sponge-like matrix of 80% hydroxyapatite and 20% sugar cross-linked porcine collagen

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Bio-Oss® Collagen
Description: 90% bovine derived xenograft granules and 10% porcine collagen
Study: NCT02488616

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 5-day intervention with single-hormone closed-loop strategy
Description: A sensor will be inserted on the day prior to the first day of the intervention by the participants. On the first day of the intervention, participants will be admitted to the clinical research facility anytime between 8:00 am and 11:30 am. Training on connection and disconnection of the system, meal boluses, etc. will be given.~Competency on the use of study devices will be assessed by a team member. Only participants demonstrating competency on use of study devices will be allowed to continue to the home study phase. Participants will be advised to continue with study intervention at home for the next 5 days.
Study: NCT02013752

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Perineal protection device.
Description: A device used to reduce perineal tears during delivery of the baby.
Study: NCT02488616

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 5-day intervention with sensor-augmented pump therapy
Description: A sensor will be inserted on the day prior to the first day of the intervention by the participants. The participant will also have to install the study insulin pump. Participants will be advised to continue with study intervention at home for the next 5 days.~Participants will have been previously shown how to use the study insulin pump.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Insulin pump
Description: MiniMed® Paradigm® Veo™, Medtronic

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Insulin pump
Description: MiniMed® Paradigm® Veo™, Medtronic

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Continuous glucose monitoring system
Description: Enlite sensor®, Medtronic

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Continuous glucose monitoring system
Description: Enlite sensor®, Medtronic
Study: NCT02013752

Intervention type: DEVICE
Group type: OTHER
Intervention: Perineal protection device.
Description: A device used to reduce perineal tears during delivery of the baby.
Study: NCT05616403

Intervention type: OTHER
Intervention: No intervention
Description: This is an observational study without any intervention
Study: NCT02488616

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin
Description: Participant's usual fast-acting insulin analog will be used: Lispro (Humalog), Aspart (NovoRapid) or Glulisine (Apidra)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin
Description: Participant's usual fast-acting insulin analog will be used: Lispro (Humalog), Aspart (NovoRapid) or Glulisine (Apidra)
Study: NCT02332213

Intervention type: PROCEDURE
Intervention: Breath sampling for volatile marker detection
Description: Acquisition of two exhaled breath samples of alveolar air to be analysed by GCMS and nanosensor technology

Intervention type: PROCEDURE
Intervention: Breath sampling for volatile marker detection
Description: Acquisition of two exhaled breath samples of alveolar air to be analysed by GCMS and nanosensor technology

Intervention type: PROCEDURE
Intervention: Breath sampling for volatile marker detection
Description: Acquisition of two exhaled breath samples of alveolar air to be analysed by GCMS and nanosensor technology
Study: NCT01958125

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: gammaCore
Description: Vagal stimulation

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: gammaCore
Description: Vagal stimulation
Study: NCT03296293

Intervention type: OTHER
Group type: OTHER
Intervention: PEEP at 5cmH2O
Description: Effect of PEEP at 5cmH2O on ICP

Intervention type: OTHER
Group type: OTHER
Intervention: PEEP at 5cmH2O
Description: Effect of PEEP at 5cmH2O on ICP

Intervention type: OTHER
Group type: OTHER
Intervention: PEEP at 5cmH2O
Description: Effect of PEEP at 5cmH2O on ICP

Intervention type: OTHER
Group type: OTHER
Intervention: PEEP at 10cmH2O
Description: Effect of PEEP at 10cmH2O on ICP
Study: NCT02332213

Intervention type: PROCEDURE
Intervention: Breath sampling for volatile marker detection
Description: Acquisition of two exhaled breath samples of alveolar air to be analysed by GCMS and nanosensor technology

Intervention type: PROCEDURE
Intervention: Breath sampling for volatile marker detection
Description: Acquisition of two exhaled breath samples of alveolar air to be analysed by GCMS and nanosensor technology
Study: NCT03296293

Intervention type: OTHER
Group type: OTHER
Intervention: PEEP at 10cmH2O
Description: Effect of PEEP at 10cmH2O on ICP

Intervention type: OTHER
Group type: OTHER
Intervention: PEEP at 10cmH2O
Description: Effect of PEEP at 10cmH2O on ICP

Intervention type: OTHER
Group type: OTHER
Intervention: PEEP at 15cmH2O
Description: Effect of PEEP at 15cmH2O on ICP

Intervention type: OTHER
Group type: OTHER
Intervention: PEEP at 15cmH2O
Description: Effect of PEEP at 15cmH2O on ICP

Intervention type: OTHER
Group type: OTHER
Intervention: PEEP at 15cmH2O
Description: Effect of PEEP at 15cmH2O on ICP